Matthew Hebden Porteus

This inventor holds 16 USPTO granted patents and 33 published patent applications, plus 1 CIPO patent and 4 EPO patents. Top assignees: Leland Stanford Junior University, Vertex Pharmaceuticals, Inc., Agilent Technologies, Inc.. Active years: 2020-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Matthew Hebden Porteus. Retrieved from https://idiyas.com/inventor/matthew-hebden-porteus

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 16 (Patent Applications = 33)

% Patents Active = 100.0

CIPO Patents = 1 (Patent Applications = 1)

EPO Patents = 4 (Patent Applications = 18)

Average Co-Inventor Count = 2.5

ph-index = 3

Forward Citations = 23(Granted Patents)

Location History:

Stanford, CA (US) (2020 - 2024)
Cambridge, MA (US) (2024)

Company Filing History:

12 out of 5,512

Leland Stanford Junior University

patents

4 out of 1,167

Vertex Pharmaceuticals, Inc.

patents

2 out of 4,731

Agilent Technologies, Inc.

patents

4. 1 out of 1

University and Agilent Technologies, Inc.

patent

where one patent can have more than one assignee

Years Active: 2020-2026

Loading Chart...

16 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12735711 - TARGETING THE HUMAN CCR5 LOCUS AS A SAFE HARBOR FOR THE EXPRESSION OF THERAPEUTIC PROTEINS (2026-09-15),

2. 12540311 - CRISPR-BASED FOXP3 GENE ENGINEERED T CELLS AND HEMATOPOIETIC STEM CELL PRECURSORS TO TREAT IPEX SYNDROME PATIENTS (2026-02-03),

3. 12442016 - Scarless genome editing through two-step homology directed repair (2025-10-14),

4. 12134767 - Materials and methods for treatment of hemoglobinopathies (2024-11-05),

5. 12129471 - Materials and methods for treatment of human genetic diseases including hemoglobinopathies (2024-10-29),

6. 12043843 - Materials and methods for treatment of hemoglobinopathies (2024-07-23),

7. 11903969 - Genome editing of graft-derived T-cells for post-transplant immunotherapy (2024-02-20),

8. 11851652 - Compositions comprising chemically modified guide RNAs for CRISPR/Cas-mediated editing of HBB (2023-12-26),

9. 11773409 - CRISPR/Cas 9-mediated integration of polynucleotides by sequential homologous recombination of AAV donor vectors (2023-10-03),

10. 11692202 - Scarless genome editing through two-step homology directed repair (2023-07-04),

11. 11634732 - Pharmaceutical compositions comprising gene-corrected primary cells (2023-04-25),

12. 11535846 - Chemically modified guide RNAS for CRISPR/Cas-mediated gene regulation (2022-12-27),

13. 11492646 - Nuclease-mediated genome editing of primary cells (2022-11-08),

14. 11306309 - Chemically modified guide RNAs for CRISPR/CAS-mediated gene regulation (2022-04-19),

15. 11193141 - Nuclease-mediated genome editing of primary cells and enrichment thereof (2021-12-07),

Title: The Innovative Journey of Matthew Hebden Porteus

Introduction: Matthew Hebden Porteus is a renowned inventor based in Stanford, CA (US), known for his groundbreaking contributions in the field of biotechnology and genetic engineering.

Latest Patents: Matthew Hebden Porteus holds several patents related to gene editing technologies and therapies aimed at treating genetic disorders effectively.

Career Highlights: With a distinguished career in academia and research, Matthew Hebden Porteus has made significant strides in developing innovative gene therapies, particularly in the treatment of genetic diseases such as sickle cell anemia.

Collaborations: Throughout his career, Matthew Hebden Porteus has collaborated with leading researchers, biotech companies, and medical institutions to further advance the field of gene editing and personalized medicine.

Conclusion: Matthew Hebden Porteus continues to be a driving force in the field of biotechnology, with his pioneering work paving the way for revolutionary advancements in genetic therapies and personalized medicine.

Profile summary based on public USPTO records.